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Abstract 
BACKGROUND: Human epidermal growth factor receptor 2 (HER-2) is an oncogenic gene and a well-
established therapeutic target in several cancers including breast and ovary.  
AIM: The present study aimed to compare HER-2 expression status with histological grades as well as 
Clinicopathological parameters including age, bleeding per rectum, pain/burning sensation in defecation and 
exercise.  
METHODS: Her-2 status was assessed by immunohistochemistry (IHC).  
RESULTS: Results of the study shows that 40.96% patients were Her-2 positive for expression and a statistically 
significant difference (p-value = 0.004) was observed in histological grades where most of the cases were of 
grade II. We also observed a significant difference in histological grades with gender (p-value = 0.04), as well as 
in both the age groups ≤ 55 years and > 55 years (p-value = < 0.0001). Patients with the bleeding rectum and 
pain/burning sensation in defecation had grade II/III tumours (93.4%, 88.7%) respectively. A significant 
association was observed between bleeding per rectum and pain/burning sensation in defecation. About 95% of 
patients with pain/burning sensation in defecation had bleeding per rectum.  
CONCLUSION: To conclude, Her-2 can be a potential prognostic marker in CRC. The role of age, tumour grade 
and bleeding per rectum/burning sensation in defecation are of significant worth. Thus, CRC cases of high grades 
can be screened for HER-2/neu positivity so that they can be subjected to mAb-based individualised therapy. 
 
 
 
 
 
 
 
Introduction 
 
Colorectal cancer is the third most 
widespread malignancy globally affecting both the 
genders, with an estimated 1.4 million new cases 
annually. It accounts for about 9.7% of all cancer [1]. 
In the earlier studies, it was observed that HER-2 is 
associated with tumorigenesis, metastases of disease 
and poor clinical prognosis. The ligand binding causes 
receptor dimerisation and passes signal by auto-
phosphorylation of HER-2 tyrosine kinase domain and 
activates the target proteins, such as mTOR, Src, 
STAT, MAPK [2]. In tumour cells, the Her-2/neu gene 
is amplified in approximately 20% to 25% of all cases 
instead of having twin copies per cell; there may be as 
many as 50 or 100 c-erb-B2 gene copies per cell [3]. 
This gene amplification even results in overexpression 
of Her-2/neu at both the mRNA and protein levels; 
amounting approximately 2,000,000 Her-2/neu 
molecules in a single tumour cell, instead of the 
20,000 to 50,000 molecules per cell found in normal 
cells. When Her-2/neu is overexpressed at these 
abnormally high levels, the kinase activity becomes 
constitutively activated possibly due to auto-activation 
of accumulating Her-2/neu molecules [4]. 
The overexpression of Her-2/neu protein on 
the cell membrane leads to hypersensitivity of the 
cancer cell to the growth factors. Thus, it acts as a 
proto-oncogene. The role of EGFR (HER-2) is well 
established in breast cancer pathogenesis and is also 
one of the most important prognostic marker and 
target for the gene related therapy in breast cancer 
management. HER-2 overexpression in malignant 
cells intensifies metastatic potency and invasiveness 
[5]. The role of HER-2 in carcinogenesis has been 
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established in a rodent model by both In vitro as well 
as In vivo ways by the formation of tumours upon 
HER-2 amplification. Some recent studies highlighted 
novel mechanisms of HER-2 regulation that can be 
targeted for the treatment of cancer [6], [7].  
Thus, the present study aimed to evaluate the 
immunohistochemical expression of HER-2/neu and 
its correlation with histological grade as well as 
clinicopathological parameters in colorectal cancer. 
The outcome of the study will help in establishing Her-
2/neu as a potent prognostic marker for CRC and 
further helps in the management of Her-2 positive 
cases of CRC with any single treatment regime solely 
based on Her-2 expression, which again directs us 
towards the need of individualised therapy. Secondly, 
the association of Her-2 expression with 
clinicopathological parameters will help in establishing 
a better diagnosis and understanding aetiology of the 
disease.  
 
 
Material and Methods 
 
The present study was conducted at the 
Medical Biotechnology Laboratory, Department of 
Biotechnology, Jamia Millia Islamia, New Delhi, India 
after ethical approval from the Institutional Ethics 
Committee (17/9/10/JMI/IEC/2015). In the present 
study 83 (Eighty-three) unrelated subjects of Indian 
origin were included which were histologically 
diagnosed with colorectal cancer.  
A tissue biopsy/colectomy sample was 
collected from each patient after taking their consent, 
and their tissues were stored in 10% Buffered 
Formaldehyde (Merck) at room temperature for 
immunohistochemical analysis. The adjacent non-
cancerous tissue of the biopsies was taken as control 
for the IHC analysis. For the study purpose, the 
relevant clinical history of each case was collected in 
the pretext perform for correlation with 
clinicopathological parameters. 
The tissue biopsy was processed for making 
paraffin embedded blocks. Further, the thin sections 
of size (4 µm) from all cases were cut by using 
ultrathin microtomy. All the cases were routinely 
processed, and Haematoxylin & Eosin staining was 
done for diagnosis and histological grading. All these 
cases were graded into one of three histological 
grades using WHO criteria as Grade I/II/III 
(well/moderate/poorly differentiated) respectively. 
Following the routine histological examination, these 
cases were further studied for expression of proto-
oncogene Her-2/neu using Immuno-histochemical 
stains. 
The Immuno-histochemical stains were 
performed using Avidin-Biotin technique [8]. Thin 
sections of paraffin block were cut using microtome 
and taken on poly-L-lysine coated slides. The sections 
were deparaffinized in three changes of xylene for 5 
minutes each. Three changes of acetone were given 
for 5 minutes each. The slides were then washed in 
running tap water for 2-5 minutes. The slides were 
then given three changes of P.B.S. buffer. 0.03% 
H2O2 was prepared in methanol, and then the slides 
were kept in this solution for 30 minutes on a shaker. 
The peroxide block was discarded, and then three 
changes of P.B.S. buffer was given. Antigen retrieval 
was done by the microwave oven method [9]. After 
antigen retrieval, blocking was done using BSA 
(Merck). Immunohistochemistry is the technique 
utilised for the study of localisation of antigens in 
tissue sections using labelled antibodies as specific 
reagents through antigen-antibody interactions. The 
primary antibody for Her-2/neu was, Purified mouse 
anti-human Monoclonal antibody from (Novacastra, 
USA); the secondary antibody, tertiary antibody and 
DAB used was from (Novacastra, USA) 
Stained slides were evaluated independently. 
Whole tumour area was observed, and overall 
percentage positivity of tumour cells for Her-2/neu has 
counted under x 400 magnification. For Her-2/neu, 
membranous staining was taken as real positivity. 
Based on the percentage of positive cells, Her-2/neu 
cases were graded into one of three grades as 
follows: Grade I: < 30% tumour cells positive, Grade 
II: ≥ 30% tumour cells positive (showing membranous 
as well as cytoplasmic staining), Grade III: ≥ 30% 
tumour cells positive (showing only membranous 
staining). 
The Image J program and it’s IHC profiler 
plugin (based on colour deconvolution) was used for 
analysis of captured images. The results are in the 
form of a histogram depicting count and intensity 
peaks as well as a log file characterising the 
negativity/positivity, its magnitude and % categorical 
values accordingly. 
Considering a large number of similar values 
in the categorical data analysis was done. The 
expression of HER-2 was divided into positive and 
negative cases. The differences between the groups 
were studied by Fischer’s exact test and other 
appropriate algorithms. All the statistical analysis was 
done by using SPSS 16 software. 
 
 
Results 
 
In the present study, a total number of 83 
cases of colorectal carcinoma were studied. The age 
range (43) of all the cases in the study was between 
30 to 73 years. The mean age of cases in the study 
group was 55.9 years, while the median age was 56 
years and mode age came out to be 54 years. So, we 
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divided patients into two groups ≤ 55 years and > 55 
years of age (Table 1). 
Table 1: Clinicopathological characteristics of patients 
Gender Age 
Bleeding per 
Rectum 
Pain/Burning 
Sensation in 
Defecation 
Exercise 
Variable: n (%) {Total samples-83} 
Male: 63 (75.9 
%) 
≤ 55 years: 
38 (45.8 %) 
Yes: 76 (91.6 
%) 
Yes: 80 (96.4%) 
High: 10 (12.0 %) 
Female: 20 
(24.1 %) 
> 55 years: 
45 (54.2 %) 
No: 7 (8.4 %) No: 3 (3.6 %) Low/Moderate: 73 
(88.0 %) 
 
A significant difference was observed in the 
distribution of histopathological tumour grades among 
genders (p = 0.04). In both genders, grade II a tumour 
was most common. CRC patients in ≤ 55 years of age 
group, were mostly in grade I (31.6%) and grade II 
(63.1%), only 5.3% patients were in grade III.  
 
 
Patients in > 55 years of age group showed 
that patients were in grade II (64.4%) and III (35.5%) 
and the difference among age groups were found to 
be significant (p < 0.0001) (Table 2). 
Table 2: Association of gender and age with histological 
grades in CRC patients 
N = 83 Grade I Grade I Grade III p-value 
Male (63) 7 (11.1%) 39 (61.9%) 17 (27%) 
0.04* 
Female (20) 5 (25%) 14 (70%) 1 (5%) 
≤ 55 years (38) 12 (31.6%) 24 (63.1%) 2 (5.3%) 
< 0.0001* 
> 55 years (45) 0 (0%) 29 (64.4%) 16 (35.5%) 
 
It has been observed that cases which 
reported bleeding with rectum were either grade II/III 
tumours. However, patients who do not report 
bleeding were of grade I a tumour, and the difference 
among them was found to be significant (p < 0.0001).  
 
Patients who had burning sensation in 
defecation were either grade II/III (88.7%) however, 
patients who do not report burning sensation in 
defecation were of grade I a tumour (100%), and the 
difference among them was found to be significant (p 
= 0.002) (Table 3). 
Table 3: Association of bleeding per rectum and pain/burning 
sensation in defecation with histopathological grades in CRC 
patients 
Clinical status Grade I Grade II + Grade III p-value 
Bleeding per rectum 
Yes (76) 5 (6.6%) 71 (93.4%) 
< 0.0001* 
No (7) 7 (100%) 0 (0%) 
Pain/Burning Sensation in Defecation 
Yes (80) 9 (11.3%) 71 (88.7%) 
0.002* 
No (3) 3 (100%) 0 (0%) 
 
A significant association (p = 0.0004) was 
observed between burning sensation in defecation 
with bleeding per rectum.  
 
 
In the study group, it has been observed that 
most of the patients had bleeding per rectum (95%) 
with pain/burning sensation in defecation, only 5 % did 
not show any bleeding per rectum, however bleeding 
per rectum was also not observed in patients who did 
not show any pain/burning sensation in defecation 
(Table 4). 
Table 4: Association of pain/burning sensation in defecation 
with bleeding per rectum in CRC patients 
Clinical status Pain/Burning Sensation in Defecation p-value 
Bleeding per rectum Yes (n = 80) No (n = 3) 
Yes (76) 76 (95%) 0 (0%) 
0.0004* 
No (7) 4 (5%) 3 (100%) 
 
CRC patients with a high level of 
exercise/physical activity showed no significant 
difference in the distribution of tumour grade in 
comparison to patients with low/moderate levels of 
exercise/physical activity but, it can also be seen that 
the number of patients with high level of activity 
(10/83, 12%) is very less in comparison to the patients 
with low/moderate level of physical activity (73/83, 
88%). Though physical activity level didn’t show any 
significant difference in the distribution of tumour 
grade, in the present study group, it was observed 
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that physical activity is helpful in preventing the onset 
of cancer as cited in previous research studies (Table 
5). 
Table 5: Association of exercise with histopathological grades 
in CRC patients 
Exercise Grade I Grade II Grade III p-value 
High (10) 1 (10%) 8 (80%) 1 (10%) 
0.51 
Low/Moderate (73) 11 (15.0%) 45 (61.6%) 17 (23.4%) 
 
Histological sections of 83 colorectal tumour 
cases were incubated with anti-Her-2/neu purified 
mouse anti-human monoclonal antibody. It was found 
that 49 (59.04%) cases failed to demonstrate any 
staining while the remaining 34 (40.96%) cases 
stained positive for Her-2/neu.  
 
 
It was found that Her- 2/neu expression was 
positive in 2 (16.7%), 19 (35.9%) and 13 (72.2%) 
cases among grade I, grade II, and grade III tumours 
respectively and the differences were found to be 
significant (p = 0.004) (Table 6).  
 
 
 
The Image J program and it’s IHC profiler 
plugin (based on colour deconvolution) was used for 
analysis of captured images. The results are in the 
form of a histogram depicting count and intensity 
peaks as well as a log file characterising the 
negativity/positivity, its magnitude and % categorical 
values accordingly. Immunohistochemical expression 
observed was validated with Image J program and the 
results were found to be in concordance. 
Table 6: Distribution of Her-2 immunohistochemical expression 
status among different tumour grades of CRC patients 
Variables Her-2 +ve (n = 34) Her-2 -ve (n = 49) P value 
Histopathological grade 
Grade I (12) 2 (5.9%) 10 (20.4%) 
0.004*
 
Grade II (53) 19 (55.9%) 34 (69.4%) 
Grade III (18) 13 (38.2%) 5 (10.2%) 
 
 
 
Discussion 
 
Colorectal cancer is the third most common 
malignancy globally affecting both the sexes, with an 
estimated 1.4 million new cases annually. With global 
urbanisation and economic transition, adoption of 
western dietary habits and lifestyles and increasing 
life expectancy in developing nations, the incidence of 
colorectal cancer is rising steeply. An increasing trend 
in the incidence rates of Colorectal cancer in India has 
been reported from the various population-based 
studies.  
Colorectal cancer is a multifactorial disease 
with various etiological and medical physiognomies. 
Age, personal history, dietary habits and lifestyle are 
the major risk factors for colorectal cancer. The 
chances of CRC diagnosis raises after 40 years of 
age, gradually increasing from age 40, rise steeply 
after 50 years of age [10].  
In the present study, all 83 cases of colorectal 
carcinoma were distributed in the range of 30 to 73 
years. In our study group, there were 38 cases in ≤ 55 
years of age, and 45 were in > 55 years of age. Hence 
the prevalence rate showed a positive trend with an 
increase in the age of patients.  
The mean, median, and mode age in our 
study come out to be 55.9, 56 and 54 years 
respectively. According to National cancer registry 
programme, hospital-based cancer registry, 2012 the 
mean age at diagnosis is 45 years in Indian 
population which is similar to mean age observed in 
developed nations of the west as stated by National 
Cancer Institute, USA. Over-expression of Her-2/neu 
has been notably associated with increased cellular 
survival, increased proliferation and decreased the 
apoptotic potential of cells leading to malignant 
transformation and maintenance of the associated 
malignancy [11]. A very scarce data is available 
particularly from Asian and south-east Asian region to 
indicate expression of Her-2/neu in patients with 
colorectal adenocarcinomas.  
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Overexpression of Her-2/neu in colorectal 
cancer shows a wide range of variability between 0-
84% in different studies [12]. In neoplastic cells, 
dysregulation of the mentioned pathways and also 
increased expression of HER2/neu promotes tumour 
cell growth, progression and migration [13]. 
Overexpression of the HER2/neu receptor is detected 
in 25%-35% of breast cancer patients and has been 
known as an important prognostic and predictive 
factor [14]. In the present study, the overall expression 
rate of Her-2/neu was 40.96% which was confined 
mainly in the membrane with intermittent cytoplasmic 
localisation. This was in accordance to few studies 
which reported both membranous as well as 
cytoplasmic overexpression with rates streaking up to 
the tune of 60% [19]. On the contrary, most of the 
studies reported the rate of membranous 
overexpression between zero and 15% [17], [19]. 
According to histological grade, its expression varied 
from 16.66% (2/12) in grade I tumors to 72.22 % 
(13/18) in grade III tumors. Thus, Her-2/neu 
expression was positively related to histological grade, 
and the difference in expression rate across different 
grades was statistically significant p-value = 0.0045 (*, 
p < 0.05). Our results are in concordance with 
previous studies of [17]; these studies also showed 
very similar positive correlation between Her-2/neu 
expression and histological grades in their respective 
studies.  
This positive correlation between Her-2/neu 
expression and histological grade accounts for the 
poor prognostic significance of Her-2/neu in case of 
colorectal carcinoma. Based on these findings only 
this gene has become a target for the successful 
management of CRC. Further, in the present study 
group, most of the cases reported bleeding per rectum 
and pain/burning sensation in defecation showed to 
have grade II/III a tumour and those who do not report 
was found to be in grade I a tumour. Hence, 
pain/burning sensation in defecation and bleeding per 
rectum are important indicators for high-grade CRC.  
It has been reported that the (grade II) 
moderately differentiated carcinoma was the most 
common type and explained that the variation 
between different studies be related to the 
randomised selection and also small sample size [18], 
[20]. In clinicopathological parameters role of age, 
tumour grade and bleeding per rectum/burning 
sensation in defecation are significant in the diagnosis 
of CRC. Further, the Her-2 positive cases especially 
with high grades of CRC can be subjected to mAb-
based individualised therapy targeting Her-2/neu. 
Therefore, we hypothesise that Her-2 may be a potent 
prognostic marker in CRC and can play a pivotal role 
in the better management of the disease.  
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